CureVac

Tubingen, Germany Founded: 2000 • Age: 26 yrs Listed Acquired By BioNTech
mRNA-based therapeutics against cancer and infectious diseases are developed.

About CureVac

CureVac is a publicly listed company based in Tubingen (Germany) founded in 2000 by Florian Von Der Mulbe, and was acquired by BioNTech in June 2025. MRNA-based therapeutics against cancer and infectious diseases are developed. CureVac has raised $975.35 million across 15 funding rounds from investors including BioNTech, Gates and Gates Foundation. The company has 660 employees. CureVac has completed 1 acquisition, including Frame Therapeutics. CureVac was last valued at $1.25 billion in June 2025. Its website curevac.com draws about 21 thousand monthly visits. CureVac offers products and services including mRNA Technology Platform and mRNA COVID-19 Vaccine. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is CureVac AG.

Company details

CureVac was established in 2000 in Tubingen, Germany, within the biotechnology sector. mRNA technologies are employed to create therapeutics targeting cancer and infectious diseases. RNAntibody platforms are used to produce functional antibodies and proteins from mRNA. Key investigational assets include CV9104, a vaccine for prostate cancer that activates immune responses, CV8102 for cutaneous melanoma, and CV9202 for non-small cell lung cancer. Focus remains on immunotherapy advancements across Europe.

  • Headquarters Tubingen, Germany
  • Employees 660
  • Founders Florian Von Der Mulbe
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website curevac.com
  • Social LinkedIn X Facebook YouTube
  • Acquired by BioNTech (Jun 2025)
  • Legal Name Curevac N.V.
Key Metrics
  • Annual Revenue
    $578.9 M (USD)
    896.07
    as on Dec 31, 2024
  • Net Profit
    $175.44 M (USD)
    162.37
    as on Dec 31, 2024
  • EBITDA
    $243.15 M (USD)
    188.28
    as on Dec 31, 2024
  • Total Equity Funding
    $975.35M (USD)

    in 15 rounds

  • Latest Funding Round
    $299M (USD), Grant

    Sep 2020

  • Investors
    BioNTech

    & 16 more

  • Employee Count
    660
  • Investments & Acquisitions
  • Acquired by
    BioNTech

    (Jun 2025)

Products & Services of CureVac

CureVac offers a comprehensive portfolio of products and services, including mRNA Technology Platform and mRNA COVID-19 Vaccine.

mRNA Technology Platform
Biotech Platform

Platform for developing mRNA-based medicines and vaccines.

mRNA COVID-19 Vaccine
Vaccine Development

Program focused on mRNA vaccines for COVID-19 prevention.

Apps and channels of CureVac

its YouTube channel CureVac has 618 subscribers and 7 videos.

CureVac
YouTube 618 subscribers 7 videos Science & Technology
Open channel

Videos from CureVac

The most watched videos on CureVac's YouTube channel, CureVac (618 subscribers). Click a video to play it here.

How does it work? – Mode of action video
13.9K views
Wie funktioniert's? – Video zur Wirkungsweise
12.3K views
About CureVac - Get to know the RNA people
5.3K views
Spotlight on CureVac – the RNA people
3K views

More on CureVac.

Funding Insights of CureVac

CureVac has successfully raised a total of $975.35M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $299 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $975.35M
  • Total Rounds 15
  • Last Round Grant β€” $299M
  • First Round $3.41M

    (Jun 2003)

  • Investors Count 17

Latest 10 of 15 funding rounds of CureVac with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2020$299MGrant––
–
Jul 2020$126MSeries F–Qatar Investment Authority
–
Jul 2020$171MSeries F–GSK
–
Jul 2020$84.33MDebt – Conventional––
Jun 2020$343MSeries F–Bundesregierung
–
Jun 2019$10.29MGrant––
Feb 2019$34.1MGrant––
Feb 2018Series E–Gates Foundation
–
Nov 2016$29.5MSeries E–Baden-Wurttemberg Medical Care Agency, L-Bank
–
Nov 2015$110.25MSeries E–Baillie Gifford
Valuation history
DateValuationStage
Premium access

Full valuation and stage history of CureVac

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $1.25B (Jun 2025). 17 investors in total: 17 institutional.

Investors in CureVac

CureVac has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Gates and Gates Foundation.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Healthcare investments are targeted by this private equity firm.
2017cepi.netOslo, Norway
Investments are made in life and health sciences companies.
dievini.deGermany
Finance and advisory services for infrastructure projects are provided.
1958eib.orgLuxembourg, Luxembourg
hyfinityfund.com
A sovereign wealth fund backed by Qatar, managing investments and funds.
2005qia.qaDoha, Qatar
Developer of pharmaceuticals and vaccines for various therapeutic areas
1715gsk.comBrentford, United Kingdom
Official information and updates are provided by the German Federal Government.
bundesregierung.deBerlin, Germany
Administration of patents and trademarks in the United States.
uspto.gov
Legal services on patents and innovation are provided across Europe.
1998epo.orgMunich, Germany
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
Premium access

Investor details for CureVac

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of CureVac

113 people are tracked at CureVac (47 in leadership, 4 in board & advisors, 62 in team); the tracked headcount is 660.

NameRoleGroup
Florian Von Der Mulbe
Co-Founder & CPOLeadership
Alexander Zehnder
CEOLeadership
Malte Greune
Chief Operating OfficerLeadership
Axel Sven Malkomes
CFOLeadership
Mark Caroli
Vice President Supply Chain ManagementLeadership
Felipe Pereira
Global Director Supply Chain PlanningLeadership
Nicole Luft
Director Direct ProcurementLeadership
Thaminda Ramanayake
Chief Business & Strategy OfficerLeadership
Dr. Marco Rau
General Counsel - Executive Vice President Legal & ComplianceLeadership
Giulia Povellato
Vice President, Global Programme Head - Urinary Tract InfectionsLeadership
Miriam Schmid
Senior Director Strategic Portfolio ManagementLeadership
Inma Muniz
Project Director Digital And DataLeadership
Ulrike Gnad-Vogt
Interim Chief Development OfficerLeadership
Myriam Mendila
Chief Scientific Officer & Head, R&DLeadership
Tobias Seibel
Associate Director Translational And Clinical ScienceLeadership
Arlène Derbaix
VP Product Development Operations, Program And Portfolio ManagementLeadership
Nils Hamann
Senior Director Quality Manufacturing & QPLeadership
Dr. Dominik Esslinger
Senior Director Digital & Data Services For OperationsLeadership
Christian Ellinger
Director Business Development & LicensingLeadership
Dr. Yvonne Gebhardt
VP ManufacturingLeadership

93 more people are available in the full profile.

Premium access

Complete people profiles for CureVac

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of CureVac

CureVac is a publicly listed company on the NASDAQ with ticker symbol CVAC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 May 2021
  • Listed onLSE: 0A9E
  • Listed entityCureVac N.V.
  • Exchange sectorHealth technology
  • ISINNL0015436031
  • Share price$4.66 (-0.21% on the day) · 2026-01-07
  • Market capitalisation$1.05B
  • Price to earnings6.5
  • EPS (diluted, trailing year)$0.71
  • Volume (last session)1,149,400
  • Analyst consensusNeutral

Financials of CureVac

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2024$578.9M$175.4M$243.2M
2023$58.1M-$281.3M-$275.4M
2022$70.9M-$261.7M-$272.7M
2021$121.7M-$486.6M-$1.20B
2020$55.7M-$147.2M-$136.1M
Premium access

Detailed financial statements for CureVac

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CureVac

CureVac has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Frame Therapeutics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Immunotherapies and personalized vaccines for cancer are developed.
frametherapeutics.comAmsterdam, Netherlands2018Jun 2022$34.2M
Premium access

Complete acquisition details for CureVac

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of CureVac

7 dated milestones of CureVac across 25 years, from founding to its latest funding, stage changes and deals.

  1. Founded CureVac is founded.
  2. Funding First funding round of $3.4M.
  3. Milestone Reaches Unicorn status.
  4. Funding Latest funding round, Grant, of $299.0M.
  5. IPO Lists on the stock exchange (IPO).
  6. Acquisition Acquires Frame Therapeutics.
  7. Exit Acquired by BioNTech.

Web traffic of CureVac

The website of CureVac (curevac.com) receives about 21.2K visits a month and ranks #1,260,361 among all websites worldwide, #1,597 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    21.2K

    ▲ 9.4% vs previous month

  • Unique visitors
    8.5K

    per month

  • Global rank
    #1,260,361

    among all websites

  • Category rank
    #1,597

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with CureVac. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
immatics.com
100%
17.1K#1,492,078View details
immunocore.com
92%
11.9K#2,192,904View details
biontech.de
biontech.de
87%
#522,738–
cpmda.org.tw
cpmda.org.tw
85%
#1,393,044–
news.gbimonthly.com
news.gbimonthly.com
51%
#720,971–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Curevac

Premium access

Complete news archive for CureVac

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CureVac

CureVac was founded in 2000 and raised its 1st funding round 3 years after it was founded.

CureVac is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.

CureVac is a funded company, having raised a total of $975.35M across 15 funding rounds to date. The company's 1st funding round was a Series E of $110.25M, raised on Jun 2003.

CureVac has 660 employees.

Annual revenue of CureVac is $578.9M as on Dec 31, 2024.

CureVac was established in 2000 in Tubingen, Germany, within the biotechnology sector. mRNA technologies are employed to create therapeutics targeting cancer and infectious diseases. RNAntibody platforms are used to produce functional antibodies and proteins from mRNA. Key investigational assets include CV9104, a vaccine for prostate cancer that activates immune responses, CV8102 for cutaneous melanoma, and CV9202 for non-small cell lung cancer. Focus remains on immunotherapy advancements across Europe.

CureVac offers mRNA Technology Platform and mRNA COVID-19 Vaccine.

Yes, CureVac is publicly traded on NASDAQ under the ticker symbol CVAC.

CureVac has made 1 acquisition, including Frame Therapeutics.

CureVac has 17 investors. Key investors include BioNTech, Gates, Gates Foundation, Baillie Gifford, and European Investment Bank.

The valuation of CureVac is $1.25B as of Jun 2025.

CureVac operates through Curevac Ag.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available